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Background and Objectives French Polynesia (FP) experienced a large Zika virus (ZIKV) outbreak in 2013-2014. Flavivirus transfusion-transmission infections (TTIs) had been previously reported. We evaluated several mitigating strategies to prevent ZIKV TTIs in FP.
Material and Methods Mitigation strategies consisted of pre/postdonation symptom reporting, donor deferral, importation of plasma units from non-endemic areas, quarantine of blood components, blood screening using a laboratorydeveloped nucleic acid testing (NAT) assay and platelet pathogen inactivation (PI) using the INTERCEPT Blood Systems. The pros and cons of NAT versus PI to prevent ZIKV TTIs were determined.
Results Donor interview, deferral and component quarantine strategies were not sensitive enough to prevent subsequent detection of ZIKV RNA NAT-positive donations. A 12-week delay between the onset of outbreak and NAT implementation allowed for 30 blood products collected from 30 asymptomatic blood donors who retrospectively tested positive for ZIKV RNA by NAT to be transfused while platelet PI which was in routine use since 2010 in FP potentially prevented several cases of ZIKV TTIs.
Conclusion Nucleic acid testing and PI were used in FP to prevent ZIKV TTIs. NAT was an effective measure once implemented but is not a proactive solution. PI is a proactive solution but with only systems approved for platelets and plasma. Based on the FP experience, there is an urgent need for approved whole blood and/or red blood cell PI systems and to develop multiplex NAT to maintain the availability of the blood supply in remote areas during arbovirus epidemics.
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Background and objectives
French Polynesia (FP), a French overseas territory located in the Pacific, is a highly endemic/epidemic area for arboviruses [1] including dengue virus (DENV) found circulating in the area since World War II [2] , Zika virus (ZIKV) found responsible for the 2013-2014 outbreak during which about 11% of the population reported symptoms of infection [1, 3] , chikungunya virus (CHIKV) responsible for an outbreak in 2014-2015 [4] and Ross River virus (RRV) which has probably been circulating for the last decades [5] . After the epidemic in FP, ZIKV subsequently spread in the Pacific [6] and in the Americas [7] . In the Pacific area, multiple arboviruses can co-circulate [1, 8] .
Arbovirus transfusion-transmitted infections (TTIs) have been reported for West Nile virus (WNV) [9] , DENV [10] , yellow fever vaccine virus [11] and recently RRV [12] .
We hypothesized that ZIKV could be transmitted by blood transfusion and implemented mitigation strategies in order to prevent ZIKV TTIs in FP during the 2013-2014 outbreak.
Methods
The mitigation strategies that were immediately implemented included predonation information, deferral of blood donors with ZIKV infection-compatible symptoms, postdonation donor self-reporting of ZIKV infection-compatible symptoms, importation of plasma units from nonendemic areas, seven days passive quarantine for red blood cells (RBCs) and release excepted if donors reported postdonation symptoms of infection.
Subsequently, a laboratory-developed ZIKV nucleic acid testing (NAT) assay was developed on the basis of a ZIKV RT-PCR diagnostic assay previously described by Lanciotti et al. [13] . Blood donor sera were tested in mini pools (MPs) of three sera and individually if MP tested positive or the results were equivocal [14] . MPs were also tested for DENV according to an assay previously published for DENV diagnosis [15] . ZIKV RNA loads were determined for ZIKV RNA-positive samples as previously described [16] [17] [18] .
Pathogen inactivation (PI) by amotosalen-UVA (A-UVA) (INTERCEPT TM Cerus Corporation, Concord, CA, USA) was implemented for the treatment of platelets in FP in 2010 and has since then been used in routine to prevent DENV TTIs and was used throughout the 2013-2014 ZIKV outbreak and beyond [19] . Fresh frozen plasma units were imported from France; PI of plasmas in FP was implemented in 2014 during a chikungunya outbreak.
Investigation of the efficacy of A-UVA to inactivate DENV in fresh frozen plasma [19] was performed during the ZIKV outbreak, and investigation to demonstrate the efficacy of the system on ZIKV [18] was performed at a later time.
Results
Mitigation strategies including pre/postdonation donor screening, interview/symptom reporting and product quarantine/discarding were only partially effective to prevent ZIKV TTIs, as most infections are asymptomatic [1] . The rate of donors deferred for ZIKV infection during the predonation donor screening is unknown because those reporting symptoms of infection were discarded but were not investigated for ZIKV or other pathogen infections. According to the FP blood bank procedures, blood samples are not collected from donors discarded during the predonation screening.
The laboratory-developed NAT assay allowed for the detection of 42 (30 retrospectively and 12 prospectively)/ 1,505 (2Á8%) ZIKV RNA-positive blood donations [14] . ZIKV RNA loads in asymptomatic blood donors ranged from 2Á5x10 3 to 8Á1x10 6 copies/ml. DENV NAT detected three positive samples prospectively in the same cohort. Even though the laboratory-developed NAT assay was available 12 weeks after the onset of the ZIKV outbreak, retrospective testing was performed on donor sera collected from weeks 5 to 12 and identified 30 ZIKV RNA-positive products that had been transfused to 26 recipients (Fig. 1) . Some donors developed ZIKV symptoms up to 10 days postdonation, and none of the recipients who received a ZIKV RNA-positive blood product subsequently developed ZIKV infection-compatible symptoms [20] .
We confirmed the efficacy of A-UVA treatment to inactivate DENV and ZIKV in plasma with, respectively, >5Á61 and >6Á57 log 10 TCID 50 /mL viral reduction of infectivity, and >1Á6x10 10 and >1Á8x10 10 RNA copies/mL reduction [18, 19] . Based on our experience, the pros and cons of PI versus NAT for arboviruses in different epidemiological situations are listed in Tables 1 and 2 .
Summary/Conclusions
When ZIKV emerged in FP in late 2013, very little was known about this pathogen and nothing about possible non-vector-borne transmission of ZIKV.
The potential for ZIKV TTIs was immediately considered, and mitigation measures were implemented. Prevention of ZIKV TTIs infections was challenging because most of the cases were asymptomatic; therefore, none of the immediately implemented measures, that is clinical evaluation of donors and postdonation information reporting, was sensitive enough to detect ZIKV NAT-positive donors.
Reference ZIKV diagnostic assays were not available in late 2013, and a laboratory-developed molecular assay was implemented for both diagnostic confirmation of symptomatic cases and blood donor screening. There was a 12-week gap from the onset of the outbreak to the time that the ZIKV NAT assay was implemented. As DENV was co-circulating with ZIKV [3] , DENV NAT was also implemented. Because of the urgency to implement ZIKV and DENV NAT, there was not enough time for optimization of a multiplex ZIKV/DENV assay, and therefore, two distinct single-plex assays had to be implemented separately. This increased significantly the work load, and the cost and the burden on the staff.
Even though the NAT assay was implemented 12 weeks after the onset of the outbreak, at the time of implementation, the peak of the outbreak has already passed.
Retrospective testing of blood donor samples collected from weeks 5 to 12 showed that 30 blood products positive for ZIKV RNA had been transfused to 26 recipients. No ZIKV TT symptomatic infections were reported [20] . The first cases of documented ZIKV TTIs were published in Brazil in 2016 after the transfusion of ZIKV-contaminated platelet components [21, 22] . It is now clear that ZIKV should be a new challenge for the safety and availability of the blood supply [23, 24] ; 'however', the next emerging pathogen remains unknown and remains to come.
Pathogen inactivation is a proactive strategy [25] designed to reduce or abolish infectivity of bacteria, viruses, parasites and potentially unknown pathogens in blood products [26] . PI was implemented in FP in 2010 to prevent DENV TTIs. Efficacy of PI by A-UVA was demonstrated in plasma and platelets for WNV [27, 28] and CHIKV [29] , and in platelets for DENV [29, 30] . The (1) Not approved assay for RBCs and whole blood (2) Fractionated blood components required (3) Logistical requirements (4) Cost (5) Reduction in efficacy of blood products efficacy of A-UVA to inactivate DENV and ZIKV in plasma was subsequently demonstrated [18, 19] . Of note, the level of inactivation of ZIKV was higher than the viral load reported in asymptomatic blood donors which was found ranging from 2Á5 9 10 3 to 8Á1 9 10 6 RNA copies/mL [18] . Following the FP outbreak, the first international recommendation to prevent ZIKV TTIs was issued by the European Center for Disease Prevention and Control in 2014 [31] , and all implemented measures are now included in those from the World Health Organization, the American Association for Blood Banks and the Food and Drug Administration [32] [33] [34] . Based on our experience, NAT was an effective measure to prevent ZIKV TTIs. During the FP ZIKV outbreak, two separate laboratory-developed assays were used to detect ZIKV and DENV, but testing was expensive and time consuming. Multiplex testing is an option, but the number of pathogens that can be included in a multiplex assay is limited. Implementing NAT for all circulating pathogens would be challenging particularly in tropical or subtropical countries such as Brazil when potentially ZIKV, DENV, CHIKV, yellow fever, Mayaro and Oropouche fever viruses are co-circulating in addition to bacterial and parasite agents [35] . Identification of the aetiologic agent of an outbreak can be challenging, especially in remote areas, increasing the delay for NAT development. The first ZIKV outbreak was reported in Yap State where about 75% of the population was estimated to have been infected, but ZIKV was identified only after the end of the epidemic [36] . In Brazil, health authorities reported an outbreak of 'exanthematous disease' in late 2014 [37] and ZIKV was identified in May 2015 [38] . In 2015, a first ZIKV outbreak was reported in Africa (Cape Verde) [39] , and there is a high potential for ZIKV to spread in sub-Saharan Africa [40] . Molecular tests are rarely available and lack quality assurance programmes in most of the subSaharan African countries; blood screening often relies on various serological assays and rapid tests. In addition, the majority of blood products are used for treating pregnancy-related bleeding patients with high risk of severe complications of ZIKV infections of newborns/neonates (41] . In such settings, PI could be the best solution to prevent TT of emerging pathogens but will be difficult to implement principally because of the cost of the technology and because only 31Á5% of blood bank centres in sub-Saharan Africa prepare fractionated blood components and there is not yet PI system accredited for whole blood [41] .
Pathogen inactivation systems are now only approved for plasma and platelets treatment. PI processes for RBCs have not yet been licensed even though promising results have been obtained with photochemical processes for the treatment of whole blood (riboflavin/UVA illumination; Mirasol PRT, TERUMO BCT Inc.) and with chemical processes for the treatment of RBCs (amustaline (S-303)/ glutathione (GSH); INTERCEPT Blood System for RBCs, Cerus Corporation) [42, 43] . However, further advance development of PI methods to make them more affordable and practical for low resources countries is also needed. There is also an urgent need to develop new multiplex NAT that includes emerging pathogens. 
